ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Life sciences firm Sartorius has agreed to buy French company Polyplus for $2.6 billion. The deal, which Sartorius signed via subgroup Sartorius Stedim Biotech, brings nucleic acid delivery know-how into the firm’s portfolio. Polyplus also brings DNA vector design and plasmid engineering capabilities with it, gained in its own acquisitions in 2022. “In the dynamically growing market for cell and gene therapies, viral vectors are needed to deliver the genes of interest into cells. The development pipeline of such therapies has been growing strongly and more and more are reaching major milestones,” Sartorius Stedim Biotech’s CEO René Fáber says in a statement.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter